Why Is Biohaven Stock Falling On Thursday?

Biohaven Ltd. BHVN shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.The Division of Neurology 1 within FDA’s Office of Neuroscience informed Biohaven that they are extending the PDUFA date for the troriluzole new drug application (NDA) for spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA.If approved, tror ...